Filing Flows › Nutra Pharma (NPHC) › Q2 2025
Nutra Pharma (NPHC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Mar 25, 2026
Nutra Pharma (NPHC) reported revenue of $85K for the second quarter 2025 (Q2 2025), +63% from a year earlier and +14% from the quarter before. Operating margin was -343.7%, net earnings $370K (437.2% of revenue).
Nutra Pharma, Q2 2025: revenue $85K (+64% year over year), operating margin -343.7%, net earnings $370K, operating cash flow −$288K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $85K | +14% | +63% |
| Operating profit | −$291K | — | — |
| Net earnings | $370K | — | — |
| Operating cash flow | −$288K | — | — |
What changed
Revenue was $85K in Q2 2025, up 63% year over year and up 14% from the previous quarter.
Gross margin was 89.5%. Operating costs exceeded revenue by $291K, an operating margin of -343.7%. Net earnings were $370K. The effective tax rate was 0.0%. Non-operating items added $660K, 179% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$288K. Non-cash charges added back $3K of depreciation and $2K of share-based compensation. Working capital and other items used $663K.
Questions
What was Nutra Pharma's revenue in the second quarter 2025?
Nutra Pharma (NPHC) reported revenue of $85K for the second quarter 2025 (Q2 2025), +63% from a year earlier and +14% from the quarter before.
Was Nutra Pharma profitable in the second quarter 2025?
Operating loss was $291K (-343.7% of revenue) and net earnings $370K.
Source: Nutra Pharma 10-Q on SEC EDGAR.